KyungDong Pharm home
Over-the-Counter Medicines

Gnal-N W Soft Cap.

Product Category
Analgesics, Antipyretics & Anti-inflammatory Medicines
Active Ingredients
Ibuprofen, pamabromine, magnesium oxide, riboflavin
Appearance
Orange, oval-shaped soft capsule containing part yellow oily content and part colorless transparent liquid.
Reimbursement Code
-
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
Of 1 capsule
- Active ingredients:
Ibuprofen (BP) --- 200mg
Pharmabromine (USP) --- 25mg
Magnesium Oxide (KP) --- 50mg
Riboflavin (KP) --- 2mg
- Additive precautions Related ingredients: Yellow No. 4, Yellow No. 5
- Other additives: Yellow No. 4, soybean oil, sorbitol sorbitan liquid, butylhydroxytoluene, polyethylene glycol 600, hydrogenated palm oil, yellow lead, Yellow No. 5, Red No. 3, povidone, purified water, potassium hydroxide, lecithin, titanium oxide, gelatin succinate

2. Effectiveness
1. Headache, toothache, post-tooth extraction pain (pain), throat (throat) pain, ear pain, joint pain, neuralgia, back pain, muscle pain, shoulder pain (stiff shoulder), bruise pain, fracture pain, sprain pain (sprain pain), menstrual pain (menstrual pain), pain relief from trauma,
2. Chills (cold and shaking symptoms), fever reduction

3. Dosage and dosage
Ages 15 and older and adults: Take 1 to 3 times a day, 1 to 2 capsules per time, avoiding fasting.
The interval between doses should be at least 4 hours.

4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral artery disease, and cerebrovascular disease should use ibuprofen with careful consideration and avoid using high doses of ibuprofen (2400 mg per day). Additionally, patients with cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking) who require high doses of ibuprofen (2400 mg per day) should be carefully considered before starting long-term treatment.
Clinical studies have shown that use of high doses (2400 mg per day) of ibuprofen may slightly increase the risk of arterial thrombosis (myocardial infarction or stroke). Overall, epidemiological studies have not demonstrated an association between low doses of ibuprofen (e.g., less than 1200 mg per day) and increased risk of arterial thrombotic events.

2. The following people should not take this medicine.
1) People with a history of hypersensitivity to this drug or its components
2) People who have experienced asthma when taking this drug or its components, other antipyretic analgesics, or cold medications
3) Infants under 3 months old (newborn babies)
4) Patients who are hypersensitive to or have a history of allergy to soybean oil
5) Patients with hypersensitivity to soybeans or peanuts

3. Do not take the following medicines while taking this medicine.
Other antipyretic analgesics, cold medicine, and sedatives

4. The following people should consult a doctor, dentist, or pharmacist before taking this medicine.
1) Infants (newborns) and children under 15 years of age who are or are suspected of being infected with chickenpox or influenza (if there is a change in behavior accompanied by nausea or vomiting, consult a doctor as this may be an early symptom of Reye's syndrome, a rare but serious disease).
2) People who have a constitution that makes them, their parents, or siblings prone to hives, contact dermatitis, bronchial asthma, allergic rhinitis (nose inflammation), migraines, food allergies, etc.
3) People who have ever experienced allergic symptoms (e.g. fever, rash, joint pain, asthma, itching, etc.) due to medication
4) People with liver disease, kidney disease, thyroid disease, diabetes, high blood pressure, etc., people with weak health or high fever.
5) Senior citizens (elderly)
6) Pregnant women, women who may be pregnant, or lactating women
7) People who are receiving treatment from a doctor or dentist (people who are receiving other medications such as diabetes, gout, arthritis, anticoagulants, steroids, etc.)
8) People who have persistent or recurring gastrointestinal problems such as heartburn, stomach discomfort, or stomach pain, or have ulcers or bleeding problems
9) People who lose a lot of water due to vomiting and diarrhea, who do not absorb water, or who take diuretics
10) People taking low-dose aspirin for the purpose of preventing myocardial infarction or stroke (This drug may reduce the effectiveness of aspirin and increase the risk of serious gastrointestinal adverse reactions.)
Laboratory data have shown that ibuprofen can inhibit the platelet aggregation effect of low-dose aspirin when administered in combination with ibuprofen and aspirin (acetylsalicylic acid). Although clinical uncertainty exists regarding the extrapolation of these data, regular or long-term ibuprofen use may reduce the cardioprotective effects of low-dose aspirin.
11) Patients with fat metabolism abnormalities such as hyperlipidemia, diabetic hyperlipidemia, and pancreatitis, or patients who require careful administration of lipid emulsions
12) This drug contains Yellow No. 4 (tartrazine) and Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to these ingredients or have a history of allergy.

5. In the following cases, immediately stop taking this medicine and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during the consultation.
1) If the following symptoms appear due to taking this drug:
Rash/redness (congestion and redness), itching, nausea/vomiting, loss of appetite, constipation, stomach pain, digestive tract bleeding, stomach discomfort, dizziness, edema (swelling)
2) In rare cases where the following serious symptoms appear due to taking this medicine:
① Anaphylactic shock (anaphylactic shock): Immediately after taking, hives, edema (swelling), chest tightness, etc., along with pale complexion, cold hands and feet, cold sweat, and difficulty in breathing may appear.
② Mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome): Accompanied by high fever, severe symptoms such as rash, redness (congestion and redness), and burn-like blisters may appear on the skin of the whole body and mucous membranes of the mouth or eyes.
③ Asthma
3) If symptoms do not improve even after taking 5-6 doses
4) In very rare cases, erythema multiforme and exfoliative dermatitis may occur, as well as an unknown photosensitivity reaction, drug reaction with eosinophilia and systemic syndrome (DRESS syndrome), and acute generalized erythroderma pustulosis (AGEP).
5) Overdosage of this drug may cause metabolic acidosis.
6) It is recommended to check plasma lipid levels when administering this drug to patients expected to be at special risk due to fat overload. If the external excretion of fat is judged to be insufficient through this inspection, the administration of this drug should be adjusted appropriately. If the patient is simultaneously receiving other intravenous lipid medications, the dosage of the lipid medication should be reduced considering the amount of lipids mixed as excipients in this drug.

6. Administration to children
Do not administer to children under 2 years of age. However, if absolutely necessary, seek medical attention.

7. Other precautions when taking this drug
1) Be sure to follow the prescribed Dosage and Administration.
2) Do not continue to take it for a long period of time.
3) Do not drink alcohol when taking.
4) Severe skin adverse reactions (including exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome, and acute generalized erythrodermoid pustulosis (AGEP)), which may be serious or fatal, have been reported in connection with ibuprofen-containing products. In most cases, these adverse reactions occur within the first month of administration. If symptoms and signs of such reactions occur, ibuprofen administration should be discontinued immediately and appropriate treatment alternatives should be considered.

8. Administration to pregnant and lactating women
1) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after 30 weeks of pregnancy increases the risk of premature closure of the fetal ductus arteriosus, so use of this drug should be avoided.
2) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.

9. Storage precautions
1) Store in a place out of reach of children.
2) Avoid direct sunlight and store (closed) in a cool place with as little moisture as possible.
3) To prevent misuse and preserve quality, do not replace the product in another container.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
12 capsules/PTP

7. Period of use
24 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Gnal-N W Soft Cap.Precautions for use2025.10.10PDFThat Day Double Soft Capsule_Precautions for use + Table of changes.pdf
2Gnal-N W Soft Cap.Precautions for use2024.07.15PDFThat Day Double Soft Capsule_Change Plan + Change Comparison Table.pdf
1Gnal-N W Soft Cap.Precautions for use2024.05.22PDFThat Day Double Soft Capsule_Precautions for use.pdf